MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry
Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...
4k Views
Samsung Biologics IPO: Another Way for the Company's Relative Valuation
We used price/sales ratio for relative valuation of Samsung Biologics Co., Ltd (207940 KS) , a growing company that has yet to show an operating...
220 Views
Recap of Samsung BioLogics' First Trading Day - Foreign Institutions Net Purchased 1M Shares
Samsung BioLogics closed at ₩144,000 with 6.67% gain on its first trading day. It started with a relatively weak sentiment at the opening price of...
200 Views
Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction
As reported by Barron's on Nov 5 ("Samsung BioLogics IPO: Too Expensive"), there are still some skeptical views on BioLogics' IPO valuation....
235 Views
One World, Two Stories
Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit...
147 Views